Flavanone

Flavanone

SCHEMBL12189591

O=C1C[C@@H](c2ccccc2)Oc2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAOB P27338 12/20 1.00
AR P10275 4/20 1.00
ADORA3 P0DMS8 3/20 1.00
CYP19A1 P11511 3/20 1.00
KDM4E B2RXH2 1/20 1.00
HSD17B10 Q99714 1/20 1.00
NPC1 O15118 3/20 0.79
RAB9A P51151 3/20 0.79
MAPT P10636 2/20 0.79
CYP3A4 P08684 1/20 0.79
MAPK1 P28482 1/20 0.79
MAOA P21397 1/20 0.67
PSMB5 P28074 1/20 0.67
HSD11B1 P28845 1/20 0.64
AKR1C3 P42330 1/20 0.64
ABCB1 P08183 1/20 0.61
ABCG2 Q9UNQ0 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Flavanone SCHEMBL29470801 1.00 MAOB (1.00) MAOBARADORA3CYP19A1KDM4E
Flavanone SCHEMBL19745 1.00 MAOB (1.00) MAOBARADORA3CYP19A1KDM4E
Flavanone SCHEMBL12660199 1.00 MAOB (1.00) MAOBARADORA3CYP19A1KDM4E
Flavanone SCHEMBL29843289 1.00 MAOB (1.00) MAOBARADORA3CYP19A1KDM4E
Flavanone SCHEMBL22715765 0.98 MAOB (0.96) MAOBARADORA3CYP19A1KDM4E
Flavanone SCHEMBL11733114 0.98 MAOB (0.96) MAOBARADORA3CYP19A1KDM4E
Flavanone SCHEMBL11666711 0.92 MAOB (0.84) MAOBARADORA3CYP19A1KDM4E
Flavanone SCHEMBL28795677 0.91 MAOB (0.82) MAOBARADORA3CYP19A1KDM4E
Flavanone SCHEMBL31187243 0.90 MAOB (0.81) MAOBARADORA3CYP19A1KDM4E
SCHEMBL12660200 0.89 MAOB (0.79) MAOBARADORA3CYP19A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025091065-A1 FLAVONOID COMPOSITION GRETALS AUSTRALIA PTY LTD (AU) 2025-05-08 WO claimed
US-20230172901-A1 COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS GRETALS AUSTRALIA PTY LTD (AU) 2023-06-08 US claimed
CN-115811969-A Compositions and methods for preventing and treating fibrotic and inflammatory disorders 格雷托斯澳大利亚私人有限公司 2023-03-17 CN claimed
EP-4146194-A1 COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS Gretals Australia Pty Ltd (AU) 2023-03-15 EP claimed
WO-2021222987-A1 COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS GRETALS AUSTRALIA PTY LTD (AU) 2021-11-11 WO claimed
WO-2021108855-A1 NEUROLOGICALLY ACTIVE FLAVONOID COMPOSITIONS AND METHODS OF USE THEREOF GRETALS AUSTRALIA PTY LTD (AU) 2021-06-10 WO claimed
US-20170246353-A1 A METHOD FOR CONSTRUCTING NITRIC OXIDE-GENERATING ADHERENT COATING GUANGZHOU NANCHUANG EVEREST MEDICAL TECHNOLOGY CO., LTD. (CN) 2017-08-31 US claimed
WO-2025091065-A1 FLAVONOID COMPOSITION GRETALS AUSTRALIA PTY LTD (AU) 2025-05-08 WO disclosed
US-20250009709-A1 PRENYLATED CHALCONE AND FLAVONOID COMPOSITIONS FOR USE IN TREATING CANCER INNOX Corp. (US) 2025-01-09 US disclosed
EP-4366723-A1 PRENYLATED CHALCONE AND FLAVONOID COMPOSITIONS FOR USE IN TREATING CANCER Innox Corp. (US) 2024-05-15 EP disclosed
CN-117940121-A Isopentenylated chalcone and flavonoid compositions for the treatment of cancer 利诺士有限公司 2024-04-26 CN disclosed
WO-2024017930-A1 FRAGRANCED COSMETIC COMPOSITION COMPRISING AT LEAST ONE FLAVONOID COMPOUND, ETHANOL, A WATER-SOLUBLE COLORANT AND A FRAGRANCING SUBSTANCE L'OREAL (FR) 2024-01-25 WO disclosed
US-20230172901-A1 COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS GRETALS AUSTRALIA PTY LTD (AU) 2023-06-08 US disclosed
WO-2023283418-A1 PRENYLATED CHALCONE AND FLAVONOID COMPOSITIONS FOR USE IN TREATING CANCER INNOX Corp. (US) 2023-01-12 WO disclosed
US-11376272-B2 Methods of modulating immune activity FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2022-07-05 US disclosed
US-20210299155-A1 METHODS OF MODULATING IMMUNE ACTIVITY FLAGSHIP PIONEERING INNOVATIONS V, INC. 2021-09-30 US disclosed
WO-2021108855-A1 NEUROLOGICALLY ACTIVE FLAVONOID COMPOSITIONS AND METHODS OF USE THEREOF GRETALS AUSTRALIA PTY LTD (AU) 2021-06-10 WO disclosed
US-20200268818-A1 BONE REMODELING ACCELERATOR HOKURIKU UNIVERSITY (JP) 2020-08-27 US disclosed
US-20120231972-A1 Probe Compound for Detecting and Isolating Enzymes and Means and Methods Using the Same INSTITUTE OF CATALYSIS (CSIC) (ES) 2012-09-13 US disclosed
WO-2010105851-A1 PROBE COMPOUND FOR DETECTING AND ISOLATING ENZYMES AND MEANS AND METHODS USING THE SAME Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11376272-B2 Methods of modulating immune activity STING1, IRF3, CGAS MAOB 2398/4885AR 3244/4885ADORA3 37/4885
US-20200268818-A1 BONE REMODELING ACCELERATOR SOST, COL2A1, CXCL12 MAOB 2366/4885AR 489/4885ADORA3 837/4885
US-20250009709-A1 PRENYLATED CHALCONE AND FLAVONOID COMPOSITIONS FOR USE IN TREATING CANCER CYP46A1, NR1H3, NR1H2 MAOB 3147/4885AR 1683/4885ADORA3 4668/4885
US-20120231972-A1 Probe Compound for Detecting and Isolating Enzymes and Means and Methods Using the Same SI, GUSB, MPI MAOB 48/4885AR 3427/4885ADORA3 2034/4885
US-20210299155-A1 METHODS OF MODULATING IMMUNE ACTIVITY STING1, IRF3, CGAS MAOB 2989/4885AR 3497/4885ADORA3 38/4885
US-20230172901-A1 COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF FIBROTIC AND INFLAMMATORY CONDITIONS MMP1, COL1A1, SERPINB1 MAOB 2184/4885AR 3364/4885ADORA3 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.